249 related articles for article (PubMed ID: 28752501)
1. Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling.
Lu FF; Wang HY; He XZ; Liang TY; Wang W; Hu HM; Wu F; Liu YW; Zhang SZ
J Neurooncol; 2017 Sep; 134(2):397-405. PubMed ID: 28752501
[TBL] [Abstract][Full Text] [Related]
2. A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype.
Wang HY; Li JY; Liu X; Yan XY; Wang W; Wu F; Liang TY; Yang F; Hu HM; Mao HX; Liu YW; Zhang SZ
Oncotarget; 2016 Nov; 7(46):74895-74903. PubMed ID: 27713134
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
4. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
5. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
6. Ion channel gene expression predicts survival in glioma patients.
Wang R; Gurguis CI; Gu W; Ko EA; Lim I; Bang H; Zhou T; Ko JH
Sci Rep; 2015 Aug; 5():11593. PubMed ID: 26235283
[TBL] [Abstract][Full Text] [Related]
7. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
8. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
9. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
[TBL] [Abstract][Full Text] [Related]
10. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
[TBL] [Abstract][Full Text] [Related]
11. High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas.
Han MZ; Huang B; Chen AJ; Zhang X; Xu R; Wang J; Li XG
Oncol Rep; 2017 Feb; 37(2):903-912. PubMed ID: 28075478
[TBL] [Abstract][Full Text] [Related]
12. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
13. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.
Bao ZS; Li MY; Wang JY; Zhang CB; Wang HJ; Yan W; Liu YW; Zhang W; Chen L; Jiang T
CNS Neurosci Ther; 2014 Feb; 20(2):112-8. PubMed ID: 24279471
[TBL] [Abstract][Full Text] [Related]
15. BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas.
Bao Z; Zhang C; Yan W; Liu Y; Li M; Zhang W; Jiang T
J Transl Med; 2013 Apr; 11():100. PubMed ID: 23590708
[TBL] [Abstract][Full Text] [Related]
16. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
17. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
19. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
20. Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling.
Zhang CB; Zhu P; Yang P; Cai JQ; Wang ZL; Li QB; Bao ZS; Zhang W; Jiang T
Oncotarget; 2015 Nov; 6(34):36643-51. PubMed ID: 26436699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
